Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abatement, accredited, acetate, affirm, Alameda, alanine, alia, ALK, Allergan, alongside, alpha, ALT, alteration, aminotransferase, amylase, anticancer, APC, appraisal, aseptic, aspartate, AST, Astra, audience, auditor, AVEO, ballot, Bay, bill, biotech, blinded, bona, bridging, Brown, Cadillac, caliber, Casein, catenin, censoring, cetuximab, charitable, circumvent, cobimentinib, complement, compliant, concept, construction, context, Coordination, count, DCR, Decentralised, defray, degradation, DOR, dossier, draft, drawn, DTC, ductal, durable, durvalumab, endocrine, epacadostat, esaxerenone, esophagobronchial, etiology, evidenced, Exploratory, extrahepatic, fide, fistula, forthcoming, furniture, GDPR, genetic, Governor, GSK, head, heading, hepatorenal, highest, histology, Holdco, hypokalemia, IM, image, impede, imposition, inappropriate, Incyte, indefinitely, infusion, inoperable, instability, instance, introduce, introducing, inverse, Jerry, Justice, justification, Leasehold, led, legislature, licensor, lymphocyte, macrovascular, monoclonal, Multidisciplinary, myeloma, neck, neutrophil, nonstatutory, offshore, Ohio, operationally, panitumumab, Parkway, payoff, PCAOB, platelet, portal, prevailing, pulmonary, pursuit, radiographic, Reauthorization, reauthorize, reliant, relocate, relocation, repatriated, resold, safeguard, savolitinib, sBLA, scrutinize, Senate, Shield, smaller, soft, StemSynergy, streamline, Taihio, technique, tipiracil, tissue, tivozanib, transatlantic, transferee, translated, tremelimumab, trifluridine, turnover, UC, UK, umbrella, unascertainable, unasserted, unavailable, uncollectible, underway, unused, upper, ureter, urge, urinary, variation, vein, verify, vigorously, wild, Wnt, Zeneca
Removed:
accreted, accretion, accuse, AMG, Ariad, ArQule, assumed, attributable, bad, balloon, bearing, beneficially, cap, cGMP, close, COMET, concentrated, continuance, convert, creditworthy, cure, declare, declaring, dedicating, dedication, default, deprioritized, derive, destroyed, deterioration, diagnosed, dilution, disadvantage, dispense, dividing, emerged, employing, exceeded, exercisable, extremely, flexibility, forfeiture, fulfillment, GCP, immunodeficiency, imprisonment, inconvenient, incremental, incumbent, incurrence, inhibition, ipilumumab, lapse, largely, leverage, leveraged, lieu, long, LXR, mCRPC, misuse, molecularly, negligence, negotiated, noncancelable, notify, NPU, ocular, pediatric, planning, plant, pool, popular, postmarketing, preceding, prednisone, predominantly, premium, prepay, prioritization, prioritize, promptly, radioactive, ready, reliably, relieve, remote, removing, rendered, renewal, rental, reportable, resale, revaluation, reversal, shipment, simplified, Sobi, subleased, Subtopic, summarize, summarized, takeover, tier, tivantinib, trait, treasury, typical, unsecured, unsolicited, utility, violate, vulnerability, warehouse, workforce
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.35 Exhibit 10.35
- 10.39 Exhibit 10.39
- 10.46 Exhibit 10.46
- 10.48 Exhibit 10.48
- 12.1 Exhibit 12.1
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- Download Excel data file
- View Excel data file
Related press release
Associated EXEL transcripts
EXEL similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February 26, 2018, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 29, 2017.
/s/ Ernst & Young LLP
Redwood City, California
February 26, 2018